Disparities in hepatitis C testing in U.S. veterans born 1945–1965

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 259-265

  Sarkar, Souvik ^a,b   Esserman, Denise A ^c   Skanderson, Melissa ^d   Levin, Forrest L ^e   Justice, Amy C ^a,c,e   Lim, Joseph K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Epidemiology; HCV; Hepatitis C virus; Testing; U.S.; Variances; Veterans

Indexed keywords

HEPATITIS ANTIBODY; VIRUS ANTIBODY; VIRUS RNA; HEPATITIS C ANTIBODY;

AFRICAN AMERICAN; AGED; ANTIBODY SCREENING; ARTICLE; FEMALE; GENOTYPE; GOVERNMENT; HEALTH CARE DISPARITY; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; UNITED STATES; VETERAN; HEPACIVIRUS;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; RISK FACTORS; UNITED STATES; VETERANS;

EID: 84970005768     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.012     Document Type: Article

References (35)

1. [1] Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368 (2013), 34–44.
2. [2] Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
3. [3] Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
4. [4] Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366 (2012), 216–224.
5. [5] Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
6. [6] Sarkar, S., Lim, J.K., Advances in interferon-free hepatitis C therapy: 2014 and beyond. Hepatology 59 (2014), 1641–1644.
7. [7] Backus, L.I., Boothroyd, D.B., Phillips, B.R., Belperio, P., Halloran, J., Mole, L.A., A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol, 9, 2011, e501.
8. [8] van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
9. [9] Ly, K.N., Xing, J., Klevens, R.M., Jiles, R.B., Ward, J.W., Holmberg, S.D., The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 156 (2012), 271–278.
10. [10] Sarkar, S., Jiang, Z., Evon, D.M., Wahed, A.S., Hoofnagle, J.H., Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol 57 (2012), 946–952.
11. [11] Kraus, M.R., Schafer, A., Teuber, G., Porst, H., Sprinzl, K., Wollschlager, S., et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology 58 (2013), 497–504.
12. [12] Shiratori, Y., Imazeki, F., Moriyama, M., Yano, M., Arakawa, Y., Yokosuka, O., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132 (2000), 517–524.
13. [13] Chou, R., Cottrell, E.B., Wasson, N., Rahman, B., Guise, J.M., Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 158 (2013), 101–108.
14. [14] Holmberg, S.D., Spradling, P.R., Moorman, A.C., Denniston, M.M., Hepatitis C in the United States. N Engl J Med 368 (2013), 1859–1861.
15. [15] Kanwal, F., Lok, A.S., El-Serag, H.B., CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology 144 (2013), 478–481.
16. [16] Smith, B.D., Morgan, R.L., Beckett, G.A., Falck-Ytter, Y., Holtzman, D., Ward, J.W., Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 157 (2012), 817–822.
17. [17] Armstrong, G.L., Wasley, A., Simard, E.P., McQuillan, G.M., Kuhnert, W.L., Alter, M.J., The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006), 705–714.
18. [18] Backus, L.I., Belperio, P.S., Loomis, T.P., Yip, G.H., Mole, L.A., Hepatitis C virus screening and prevalence among US veterans in department of veterans affairs care. JAMA Intern Med 173 (2013), 1549–1552.
19. [19] Ditah, I., Ditah, F., Devaki, P., Ewelukwa, O., Ditah, C., Njei, B., et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 60 (2014), 691–698.
20. [20] Moyer, V.A., Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159 (2013), 349–357.
21. [21] Dominitz, J.A., Boyko, E.J., Koepsell, T.D., Heagerty, P.J., Maynard, C., Sporleder, J.L., et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 41 (2005), 88–96.
22. [22] Affairs UDoV. State of care for veterans with hepatitis C 2014; 2014.
23. [23] Services UDoHaH. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care and treatment of viral hepatitis; 2011.
24. [24] Butt, A.A., Justice, A.C., Skanderson, M., Good, C., Kwoh, C.K., Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 24 (2006), 585–591.
25. [25] Fultz, S.L., Skanderson, M., Mole, L.A., Gandhi, N., Bryant, K., Crystal, S., et al. Development and verification of a “virtual” cohort using the National VA Health Information System. Med Care 44 (2006), S25–S30.
26. [26] Loaeza-del-Castillo, A., Paz-Pineda, F., Oviedo-Cardenas, E., Sanchez-Avila, F., Vargas-Vorackova, F., AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 7 (2008), 350–357.
27. [27] Park, L.S., Tate, J.P., Justice, A.C., Lo Re, V. 3rd, Lim, J.K., Brau, N., et al. FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. Cancer Epidemiol Biomarkers Prev 20 (2011), 2512–2517.
28. [28] Denniston, M.M., Jiles, R.B., Drobeniuc, J., Klevens, R.M., Ward, J.W., McQuillan, G.M., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160 (2014), 293–300.
29. [29] Chak, E., Talal, A.H., Sherman, K.E., Schiff, E.R., Saab, S., Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 31 (2011), 1090–1101.
30. [30] Backus, L.I., Belperio, P.S., Loomis, T.P., Mole, L.A., Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health 104 (2014), S555–S561.
31. [31] Udompap, P., Mannalithara, A., Heo, N.Y., Kim, D., Kim, W.R., Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol 64 (2016), 1027–1032.
32. [32] Linas, B.P., Hu, H., Barter, D.M., Horberg, M., Hepatitis C screening trends in a large integrated health system. Am J Med 127 (2014), 398–405.
33. [33] Litwin, A.H., Smith, B.D., Drainoni, M.L., McKee, D., Gifford, A.L., Koppelman, E., et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 44 (2012), 497–503.
34. [34] Chhatwal, J., Kanwal, F., Roberts, M.S., Dunn, M.A., Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162 (2015), 397–406.
35. [35] Najafzadeh, M., Andersson, K., Shrank, W.H., Krumme, A.A., Matlin, O.S., Brennan, T., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 162 (2015), 407–419.